Boston, MA—August 18, 2009
CenterWatchhas entered into a three-year partnership to share its clinical trials listing database with TrialX, a health information technology startup focused on helping patients more easily and rapidly connect with relevant clinical trials worldwide.
Investigators and patients can find the same listings on www.centerwatch.com and www.trialx.com.
“One of CenterWatch’s fundamental objectives is to ensure that patients have the access they need to the thousands of clinical trials going on around the world,” says Chris Pooley, senior vice president of CenterWatch. “Likewise, it’s important that investigators have as many avenues as possible for patient recruitment. Our partnership with TrialX helps to accomplish both those goals.”
Through TrialX’s integration with a host of online services including social media sites like Twitter and YouTube, internet health portals such as Google Health and Microsoft HealthVault, and its soon-to-be released iPhone application, investigators’ studies will be exposed to a wider, targeted patient population while patients will gain access to clinical trials in hundreds of disease categories.
“TrialX is excited to partner with CenterWatch,” says Vivek Garg, co-founder of TrialX. “This agreement will allow our site to receive current, accurate clinical trials information which will ultimately support our mission to help patients find trials that match their health conditions in an easy and timely manner.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.